These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31839036)

  • 1. [Related Factors Affecting Long-term Prognosis of AML Children with Positive RUNX1-RUNX1T1].
    Teng GY; Qu WJ; Zhang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1767-1773. PubMed ID: 31839036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].
    Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical Prognostic Factors Analysis of Initially Treated AML Children with t(8;21)/RUNX1-RUNX1T1
    Fan GL; Jiang PJ; Yuan M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1510-1515. PubMed ID: 33067946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
    Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of CD19 and CD56 in AML Patients with RUNX1-RUNX1T1 Mutation and Its Clinical Significance].
    Hu ZL; Zhang F; Huang BJ; Pan SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):727-732. PubMed ID: 29950211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy].
    Yu JQ; Xue SL; Li Z; Wang J; Wang C; Chu XL; Han R; Tao T; Qiu QC; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):210-215. PubMed ID: 32311890
    [No Abstract]   [Full Text] [Related]  

  • 8. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse.
    Ommen HB; Ostergaard M; Yan M; Braendstrup K; Zhang DE; Hokland P
    Eur J Haematol; 2010 Feb; 84(2):128-32. PubMed ID: 19891700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with
    Yun JW; Bae YK; Cho SY; Koo H; Kim HJ; Nam DH; Kim SH; Chun S; Joo KM; Park WY
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia.
    Sun Y; Wang X; Chen WM; Hao Y; Li LD; Li JY; Sun K; Shi ZY; Jiang H; Jiang Q; Huang XJ; Qin YZ
    Hematol Oncol; 2024 Mar; 42(2):e3264. PubMed ID: 38461410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
    Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
    Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1.
    Li XP; Dai Y; Zhang WN; Pan MM; Mao J; Zhao B; Jiang L; Gao Y
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111178. PubMed ID: 37951201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
    Rücker FG; Agrawal M; Corbacioglu A; Weber D; Kapp-Schwoerer S; Gaidzik VI; Jahn N; Schroeder T; Wattad M; Lübbert M; Koller E; Kindler T; Götze K; Ringhoffer M; Westermann J; Fiedler W; Horst HA; Greil R; Schroers R; Mayer K; Heinicke T; Krauter J; Schlenk RF; Thol F; Heuser M; Ganser A; Bullinger L; Paschka P; Döhner H; Döhner K
    Blood; 2019 Nov; 134(19):1608-1618. PubMed ID: 31554635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
    Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Sakamoto K; Shiba N; Deguchi T; Kiyokawa N; Hashii Y; Moriya-Saito A; Tomizawa D; Taga T; Adachi S; Horibe K; Imamura T
    Br J Haematol; 2019 Nov; 187(3):372-376. PubMed ID: 31247675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
    Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L
    Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An interlaboratory comparison study on the detection of RUNX1-RUNX1T1 fusion transcript levels and WT1 transcript levels].
    Qin YZ; Zhu LW; Lin S; Geng SX; Liu SW; Cheng H; Wu CY; Xiao M; Li XQ; Hu RP; Wang LL; Liu HY; Ma DX; Guan T; Ye YX; Niu T; Cen JN; Lu LS; Sun L; Yang TH; Wang YG; Li T; Wang Y; Li QH; Zhao XS; Li LD; Chen WM; Long LY; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):889-894. PubMed ID: 31856435
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
    Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.